Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113192 | 0.78 | OPRK1 (0.40) | OPRK1ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL19217994 | 0.73 | OPRK1 (0.35) | OPRK1ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL9908407 | 0.73 | MEN1 (0.35) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL16941871 | 0.73 | OPRK1 (0.36) | OPRK1ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL20825675 | 0.72 | MEN1 (0.39) | OPRK1ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL22580075 | 0.72 | MEN1 (0.39) | OPRK1ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL19746512 | 0.70 | MEN1 (0.41) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3316247 | 0.70 | MEN1 (0.41) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL18473509 | 0.70 | CTSV (0.34) | OPRK1ALDH1A1 | |
| SCHEMBL25233759 | 0.70 | MEN1 (0.41) | OPRK1MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840495-B2 | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds | THE BROAD INSTITUTE, INC. (US) | 2023-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840495-B2 | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds | PHOSPHO1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GRIN2C | OPRK1 133/4885ALDH1A1 2435/4885MEN1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.